ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH DOCETAXEL IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTSJaafar Bennouna,Natasha B. Leighl,Karen Kelly,George R. Blumenschein,Gerard Zalcman,Christine Audebert,Carlos Gomez-Roca,Karen L. Reckamp,Jeffrey R. Infante,Primo Lara,Frances A. Shepherd,Filip Janku,Byoung Chul Cho,Keunchil Park,Fadi S. Braiteh,Robert M. Jotte,Yuehui Wu,Daniel J. Schramek,Donna S. Cox,Alexandra M. Piepszak,Yuan Liu,Olivia S. Gardner,Vijay G. R. Peddareddigari,David R. GandaraJOURNAL OF THORACIC ONCOLOGY（2013）引用 0|浏览8暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
